Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies
K.P. Liao, V. Bykerk

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis
J.E. Homik

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment?
E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus?
C.S. Lau

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists
E.C. Keystone, K.A. Papp, W. Wobeser

Articles

Lymphotoxin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?

Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort
S. Varache, D. Cornec, J. Morvan, et al

Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety

A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis
A. Svärd, A. Kastbom, M.K. Söderlin, A. Reckner-Olsson, T. Skogh

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry
J.A. Markenson, A. Gibofsky, W.R. Palmer, et al

Time to Treatment for New Patients with RA in a Major Metropolitan City
S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China
X. Feng, Y. Zou, W. Pan, et al

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression
A. Mak, Y. Liu, R.C-M Ho

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis
K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms
A.D. Askarane, I. Castrejón, T. Pincus

Late-age Onset SSc
R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc
K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group

Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies

Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial
S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi

The SPARCC Registry for SpA

Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation
S.J. Pedersen, P. Chowiennawisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych

Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPArE Trial

High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA

Prevalence of Thyroid Autoimmunity in Patients with SpA

Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene
S. Borghini, M. Fiore, M. Di Duca, et al